Astragalus polysaccharide (APS) attenuated PD-L1-mediated immunosuppression via the miR-133a-3p/MSN axis in HCC
Authors:
Open Access
- 9 September 2022
- journal article
- research article
- Published by Taylor & Francis in Pharmaceutical Biology
- Vol. 60 (1) , 1710-1720
Abstract
Astragalus polysaccharide (APS) is a new tumour therapeutic drug, that has an inhibitory effect on a variety of solid tumours. Tumour cell immunosuppression is related to the up-regulation of progr...Keywords
This publication has 36 references indexed in Scilit:
- PD-L1, inflammation, non-coding RNAs, and neuroblastoma: Immuno-oncology perspectiveSeminars in Cancer Biology, 2018
- Moesin expression by tumor cells is an unfavorable prognostic biomarker for oral cancerBMC Cancer, 2018
- Utility of miR‑133a‑3p as a diagnostic indicator for hepatocellular carcinoma: An investigation combined with GEO, TCGA, meta‑analysis and bioinformaticsMolecular Medicine Reports, 2017
- MiR‐133a‐3p Inhibits Oral Squamous Cell Carcinoma (OSCC) Proliferation and Invasion by Suppressing COL1A1Journal of Cellular Biochemistry, 2017
- MicroRNA-200b Impacts Breast Cancer Cell Migration and Invasion by Regulating Ezrin-Radixin-MoesinMedical Science Monitor, 2016
- Astragalus membranaceus: A Review of its Protection Against Inflammation and Gastrointestinal CancersThe American Journal of Chinese Medicine, 2016
- Plasma miR-15b-5p, miR-338-5p, and miR-764 as Biomarkers for Hepatocellular CarcinomaMedical Science Monitor, 2015
- Up-Regulation of PD-L1, IDO, and T regs in the Melanoma Tumor Microenvironment Is Driven by CD8 + T CellsScience Translational Medicine, 2013
- Organizing the cell cortex: the role of ERM proteinsNature Reviews Molecular Cell Biology, 2010
- PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T CellsCancer Research, 2004